Meet the UAMS Entrepreneurs Selected for 2025 Accelerator Cohort: John Arthur, M.D., Ph.D., Nephrology; Marie Burdine, Ph.D., Biochemistry and Molecular Biology; Zachary Waldrip, Ph.D., Surgical Research.
The deadline has been extended for UAMS employees to submit innovative therapeutic or drug discovery ideas to the AR Health Ventures Accelerator (ARHVA) for significant financial and administrative support toward commercialization. Selected projects receive financial grants of up to $50,000 project management, budget allocation and progress tracking. All UAMS employees are eligible to apply, including trainees and postdoctoral fellows. The full Request for Applications document outlining the application process is available on the BioVentures website, as is a detailed FAQ. Applications are due Oct. 31. For more information, contact BioVentures Senior Program Manager Stefanie Kennon-McGill, Ph.D., at skennonmcgill@uams.edu.
AR Health Ventures Accelerator proudly announces its inaugural cohort, funding innovative projects in biofilm inhibition, radiation-responsive cancer therapy, and advanced liver injury detection, marking a significant leap in medical research.
Submit your proposals for the AR Health Ventures Accelerator program by September 29th. Apply now!
The present invention describes the cloning and molecular and cellular characterization of a novel protein with homology to the IL-17 receptor. The gene was cloned by virtue of its proximity to a common site of retroviral integration in a murine acute myeloid leukemia. The gene described herein possibly codes for a novel interleukin receptor that binds an as yet unidentified cytokine ligand, and may be useful in cancer diagnostics and therapies that rely on immune system modulation.
P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis.
Novel alkylindoles that bind tightly to cannabinoid receptors and are neutral antagonists for the cannabinoid 1 receptor and agonists for the cannabinoid 2 receptor are provided. These compounds are useful for treating alcoholism and drug abuse and for treating obesity.
Provided herein are compounds, comprising Formula (I) or Formula (II), and their pharmaceutically acceptable salts. Also provided are pharmaceutical compositions comprising a pharmaceutically acceptable excipient and at least one compound of Formula (I) and (II), singly or in combination with other pharmaceutically active ingredients, such as anti-inflammatory agents or anticancer agents.
The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma.
The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for treating cancer in humans.
